Frezent Biological Solutions — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Frezent Biological Solutions is a private, preclinical-stage biotech founded in 2018 and based in San Diego, CA. The company is pioneering a novel approach to oncology by developing therapeutics that target dormant cancer cells, a key driver of aggressive and treatment-resistant recurrence. Its pipeline consists of antibodies and ADCs aimed at preventing the reactivation of these cells, addressing a significant unmet need for over 30 million cancer survivors worldwide. Frezent is actively seeking partnerships and funding to advance its programs toward clinical development.

Oncology

Technology Platform

Platform for developing antibodies and ADCs that target tumor-specific antigens essential for the metabolic reactivation of dormant cancer cells, aiming to prevent cancer recurrence.

Opportunities

The company is targeting a massive unmet need with over 30 million cancer survivors at risk of recurrence, representing a multi-billion dollar market.

Its novel approach to dormant cells positions it in a growing niche of oncology R&D with potential for high-value partnerships or acquisition if successful.

Risk Factors

High scientific risk in targeting the complex biology of dormant cancer cells.

Clinical development will be long and expensive due to the need for large, lengthy trials to prove prevention of recurrence.

The company is pre-revenue and reliant on external funding to advance.

Competitive Landscape

The field of targeting minimal residual disease (MRD) and cancer dormancy is emerging but competitive, with several academic groups and biotechs exploring similar concepts. Frezent's specific focus on metabolic dependencies of dormant cells and its initial focus on head and neck cancer may differentiate it, but it will face competition from larger, well-funded entities as the field matures.

More companies in Oncology (General) →More companies in United States →